Michael Jackson,
Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics,
Sanford Burnham Prebys Medical Discovery Institute
Dr. Jackson is responsible for the operations of the Prebys center, a 70-person, multidisciplinary Drug Discovery enterprise, which has the capabilities needed for small molecule drug discovery and drug repositioning. The overall mission is to generate a pipeline of first-in-class drugs based on breakthrough research conducted by investigators at the Institute and their collaborators.
Prior to joining SBP in 2009, Dr. Jackson spent 15 years at Johnson & Johnson developing a track record for research and development, including successfully gaining regulatory approval for several drug delivery products, as he rose through the ranks from Vice President of Discovery to President of R&D at ALZA Corporation. He received his Ph.D. from the Department of Biochemistry at the University of Dundee in Scotland and completed his post-doctoral training at The Scripps Research Institute.
|
|
|
Add to Calendar ▼2017-04-26 10:00:002017-04-26 11:00:00Europe/LondonModeling Human CNS Disease with Patient Derived Cells : Combining the Power of Stem Cells and Phenotypic Screening in Drug DiscoveryHigh Content and Phenotypic Screening 2017 in Holiday Inn, Cambridge, UKHoliday Inn, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com
